- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05742750
A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer
Camrelizumab Combined With Apatinib and Gemcitabine Plus Cisplatin as First-line Therapy for Patients With Inoperable/Metastatic Biliary Tract Cancer (BTC): An Open-label, Single-arm, Single-center, Phase Ib/II Clinical Study
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Dongsheng Zhang, M.D., Ph.D.
- Phone Number: 86-02087343795
- Email: zhangdsh@sysucc.org.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Cancer center of SunYat-sen University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject must be able to comprehend and willing to sign an informed consent form (ICF).
- Subject must have a pathologically or cytologically confirmed carcinoma (except neuroendocrine) of the biliary tract (intra-hepatic, extra-hepatic (hilar, distal) or gallbladder) that is not eligible for curative resection, transplantation, or ablative therapies. Tumors of mixed cholangiocarcinoma/hepatocellular carcinoma histology are excluded.
- Subject must be 18-75 years of age at the time of signature of the ICF.
- Subject must have an ECOG performance status of 0-1. Estimated life expectancy no less than 3 months.
- Subject may not have received prior systemic treatment (chemotherapy or targeted therapy) for advanced BTC. Prior peri-operative chemotherapy is permitted provided it was completed > 6 months from enrollment.
- Subject must have a lesion that can be accurately assessed at baseline by CT or magnetic resonance imaging (MRI) and is suitable for repeated assessment in accordance with RECIST v1.1.
Subject must have normal organ and marrow function as defined below within 14 days of study entry:
- Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L, platelets ≥ 75 × 10^9/L, or hemoglobin ≥ 9 g/dL.
- International normalized ratio (INR) < 1.5 or a prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits. Patients receiving anticoagulation treatment with an agent such as warfarin will not be candidates for the trial. Patients on anticoagulation with low molecular weight or heparinoids are protocol candidates.
- Total bilirubin ≤ 1.5 × upper limit of normal (ULN) unless liver metastasis or BTC in which case ≤ 5 × ULN is permitted at the investigator's discretion. Aspartate transaminase (AST) and Alanine transaminase (ALT) ≤ 3 × ULN.
- Creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL/min (measured or calculated by Cockcroft and Gault equation).
- Baseline left ventricular ejection fraction (LVEF) ≥ 60% measured by echocardiography or Multiple Gated Acquisition Scan (MUGA)
Exclusion Criteria:
Patients with any of the following were excluded from the study:
- Any investigational agents or study drugs from a previous clinical study within 4 weeks of the first dose of study treatment.
- Malignancies other than BTC within 5 years prior to study enrollment, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated with curative intent, or breast ductal carcinoma in situ treated surgically with curative intent).
- Prior history of brain metastasis (unless previously treated, asymptomatic and stable for at least 3 months) or organ transplant.
- Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment.
- Active bleeding during the last 4 weeks prior to screening or in the investigator's judgment, the existence of high bleeding tendency lesions such as active gastrointestinal ulcers or prominent esophageal or gastric varices.
Significant cardiovascular disease, including:
- Heart disease classified as New York Heart Association class III or IV.
- Ongoing uncontrolled hypertension.
- History of congenital long QT syndrome.
- Ongoing prolonged QT interval corrected for heart rate using Fridericia's method (QTcF) defined as ≥ 470 msec.
- History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation).
- Subjects with atrial fibrillation, that is well controlled with treatment, can be enrolled. Active heart disease including symptomatic heart failure (NYHA class 3 or 4), unstable angina pectoris, uncontrolled cardiac arrhythmia or interstitial lung disease. Prolonged QTcF interval >480 msec.
- Ongoing active, uncontrolled infection (must be afebrile for > 48 hours off antibiotics).
- With the exception of alopecia, any unresolved toxicities from prior therapy ≥Common Terminology Criteria for Adverse Events (CTCAE) Grade 2.
- Pregnancy or breastfeeding. (Women must not be pregnant or breastfeeding since study drugs may harm the fetus or child. All females of childbearing potential [not surgically sterilized and between menarche and 1 year post menopause] must have a negative screening pregnancy test.)
- History of human immunodeficiency virus infection.
- History of autoimmune disease.
- Ascertained hypersensitivity to gemcitabine, cisplatin, camrelizumab or apatinib, or drugs with similar chemical structures, or its inactive components. If there is suspicion that the subject may have an allergy, the subject should be excluded.
- Psychiatric illness, other significant medical illness, or social situation which, in the investigator's opinion, would limit compliance or ability to comply with study requirements. Judgment by the investigators that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Camrelizumab + apatinib and chemotherapies (gemcitabine and cisplatin)
Apatinib is a multi-target TKI, which selectively inhibits VEGFR-2. Camrelizumabb is a anti-human PD-1 monoclonal antibody. |
Patients received apatinib orally at 250 mg once a day irrespective of the patient weight. Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks. GP chemotherapy: Gemcitabine/Cisplatin (gemcitabine 1000mg/m2 + cisplatin 25mg/m2) will be administered on D1/D8 in every three weeks cycle and up to 8 cycles. All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of dose-limiting toxicity
Time Frame: up to day 22
|
Dose limiting toxicities will determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of combination therapy with camrelizumab + apatinib and gemcitabine plus cisplatin.
Assessed using the NCI CTCAE v5.0
|
up to day 22
|
Recommended phase 2 dose(RP2D) of apatinib
Time Frame: 12 weeks
|
To determine a RP2D of apatinib for each population of biliary tract carcinoma subjects.
|
12 weeks
|
Objective Response Rate (ORR)
Time Frame: up to 24 months
|
Defined as percentage of participants achieving assessed complete response (CR) and partial response (PR) by the investigator according to the RECIST 1.1.
|
up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: up to 24 months
|
PFS is defined as the time from enrollment to the first documented disease progression or death due to any cause, whichever occurs first.
Responses are according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by investigator
|
up to 24 months
|
Adverse Events (AE)
Time Frame: up to 24 months
|
overall incidence of adverse events (AE); incidence of grade 3 or higher AE; incidence of severe adverse events (SAE); incidence of AEs leading to discontinuation of drug use; incidence of AEs leading to suspension of drug use.
|
up to 24 months
|
Disease Control Rate (DCR)
Time Frame: up to 24 months
|
DCR was defined as the percentage of participants who have a confirmed complete response(CR) or partial response(PR) or stable disease(SD) per RECIST 1.1 as assessed by investigator
|
up to 24 months
|
Overall Survival (OS)
Time Frame: up to 24 months
|
OS is the time from enrollment to death due to any cause.
|
up to 24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dongsheng Zhang, M.D., Ph.D., Sun Yat-sen University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-OBU-GD-EC-II-005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Biliary Tract Cancer
-
ASLAN PharmaceuticalsCompletedAdvanced or Metastatic Solid Tumors | Advanced or Metastatic Biliary Tract CancerJapan
-
Gyeongsang National University HospitalSamsung Medical Center; Dong-A University; Chung-Ang UniversityTerminatedMetastatic Biliary Tract Cancer | Locally Advanced Biliary Tract CancerKorea, Republic of
-
Tianjin Medical University Cancer Institute and...CSPC Ouyi Pharmaceutical Co., Ltd.Recruiting
-
Changhoon YooUlsan University Hospital; Inje University; Kyungpook National University Chilgok... and other collaboratorsCompletedMetastatic Biliary Tract CancerKorea, Republic of
-
Asan Medical CenterCompletedMetastatic Biliary CancerKorea, Republic of
-
Shanghai Miracogen Inc.RecruitingAdvanced or Metastatic Biliary Tract CancerChina
-
Herlev HospitalBristol-Myers SquibbCompletedMetastatic Pancreatic Cancer | Metastatic Biliary Tract CancerDenmark
-
Shanghai Miracogen Inc.RecruitingAdvanced or Metastatic Biliary Tract CancerChina
-
ASLAN PharmaceuticalsWithdrawnAdvanced or Metastatic Biliary Tract Cancer
-
Seoul National University Bundang HospitalCompletedBiliary Cancer MetastaticKorea, Republic of
Clinical Trials on Camrelizumab and Apatinib Plus GP
-
Peking UniversityJiangsu HengRui Medicine Co., Ltd.Recruiting
-
Peking Union Medical College HospitalJiangsu HengRui Medicine Co., Ltd.RecruitingGestational Trophoblastic NeoplasiaChina
-
The First Affiliated Hospital of Zhengzhou UniversityRecruitingEsophageal Cancer by AJCC V8 StageChina
-
Peking Union Medical College HospitalCompletedApatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (ACABC)Cholangiocarcinoma | Hepatobiliary Neoplasm | Biliary Tract Cancer | BiomarkerChina
-
Sun Yat-sen UniversityActive, not recruitingNasopharyngeal Carcinoma | Chemotherapy Effect | Immunotherapy | Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma | Molecular Targeted TherapyChina
-
Peking University Cancer Hospital & InstituteRecruiting
-
Henan Cancer HospitalRecruitingCamrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer (CAMERA)Small Cell Lung CarcinomaChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingAdvanced Hepatocellular CarcinomaChina
-
Zhejiang UniversityHuashan Hospital; West China Hospital; The First Affiliated Hospital of Zhengzhou... and other collaboratorsUnknownHepatocellular Carcinoma | Liver TransplantChina
-
Shandong Provincial HospitalUnknown